All In Biotech

Drug Trial Radar · NCT07209761

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

532

Planned (sponsor's estimate)

Start

Oct 16, 2025

Primary completion

Sep 29, 2028

Study completion Sep 29, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or multidrug-resistant pulmonary tuberculosis. Participants are assigned to 1 of 2 cohorts based on fluoroquinolone susceptibility. In the fluoroquinolone-susceptible cohort, participants are randomized 1:1 to receive either a 4-month experimental regimen of bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin. In the fluoroquinolone-resistant cohort, participants are randomized 3:1 to receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. A total of approximately 532 participants are planned, including 432 participants in the fluoroquinolone-susceptible cohort and approximately 100 participants in the fluoroquinolone-resistant cohort. The primary efficacy endpoint is the proportion of participants with an unfavorable outcome by 12 months post-randomization. Prespecified agency-specific definitions are used for the classification of regimen changes, sputum culture conversion, relapse, and reinfection. All unfavorable outcome events will be confirmed by a blinded Endpoint Adjudication Committee.

Conditions

  • Rifampicin-Resistant Pulmonary Tuberculosis
  • Multidrug-Resistant Pulmonary Tuberculosis

Interventions

  • BedaquilineDrug

    In the BPaQM and BPaQ experimental arms, bedaquiline is administered orally at 400 mg once daily for 2 weeks, followed by 100 mg once daily for 15 weeks in the BPaQM arm or 24 weeks in the BPaQ arm. In the BPaLM and BPaL control arms, bedaquiline is administered orally at 400 mg once daily for 2 weeks, followed by 200 mg 3 times weekly for 24 weeks.

  • QuabodepistatDrug

    Quabodepistat 30 mg administered orally once daily under fed conditions, during or immediately after a meal. Quabodepistat is administered for 4 months, with a target of 120 treatment days, in the BPaQM arm and for 6 months, with a target of 180 treatment days, in the BPaQ arm.

  • PretomanidDrug

    Pretomanid 200 mg administered orally once daily for 4 months in the BPaQM arm and for 6 months in the BPaLM, BPaQ, and BPaL arms.

  • MoxifloxacinDrug

    Moxifloxacin 400 mg administered orally once daily for 4 months in the BPaQM arm and for 6 months in the BPaLM arm.

  • LinezolidDrug

    Linezolid 600 mg administered orally once daily for 6 months in the BPaLM and BPaL arms. Protocol-defined dose reduction to 300 mg once daily, temporary interruption, or discontinuation may be permitted to manage significant toxicity after consultation with the medical monitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with an unfavorable outcome by 12 months post-randomization.Time frame: From randomization through 12 months post-randomization.
  2. Proportion of participants with significant treatment-emergent adverse events (TEAEs) during treatment and through 2 weeks after treatment.Time frame: From the first dose through 2 weeks after the end of treatment, up to approximately 28 weeks.

Locations

42 sites in 10 countries. Site status is shown where the registry gives one.

  • Capital Medical University - Beijing Chest Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province

    Fuzhou, Fujian, China · Recruiting

  • The Third People's Hospital of Shenzhen

    Shenzhen, Guangdong, China · Recruiting

  • Wuhan Institute of Tuberculosis Control (Wuhan Pulmonary Hospital)

    Wuhan, Hubei, China · Recruiting

  • The Second Hospital of Nanjing

    Nanjing, Jiangsu, China · Recruiting

  • Shandong Public Health Clinical Center

    Jinan, Shandong, China · Recruiting

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital - Pneumology

    Shanghai, Shanghai Municipality, China · Recruiting

  • Public Health Clinical Center of Chengdu

    Chengdu, Sichuan, China · Recruiting

  • National Center for Tuberculosis and Lung Disease

    Tbilisi, Georgia · Recruiting

  • P.D. Hinduja Hospital & Medical Research Centre - MAHIM

    Mumbai, Maharashtra, India · Not yet recruiting

  • Rajan Babu Institute of Pulmonary Medicine and Tuberculosis (RBIPMT) - RBTB Hospital

    New Delhi, National Capital Territory of Delhi, India · Not yet recruiting

  • National Institute of Tuberculosis and Respiratory Diseases Hospital (NITRD)

    New Delhi, National Capital Territory of Delhi, India · Not yet recruiting

  • Indian Council of Medical Research (ICMR) - National Institute for Research in Tuberculosis (NIRT) (Tuberculosis Research Centre)

    Chennai, Tamil Nadu, India · Not yet recruiting

  • Jakarta Islamic Hospital - Rumah Sakit Islam Jakarta (RSIJ)

    Jakarta, Special Capital Region of Jakarta, Indonesia · Not yet recruiting

  • Rumah Sakit Umum Pusat (RSUP) Dr. Hasan Sadikin

    Bandung, West Java, Indonesia · Not yet recruiting

  • Rumah Sakit Paru Dr. M. Goenawan Partowidigdo (RSPG)

    Bogor, West Java, Indonesia · Not yet recruiting

  • Japan Anti-Tuberculosis Association Fukujuji Hospital

    Kiyose, Tokyo, Japan · Recruiting

  • IMSP Institutul de Ftiziopneumologie Chiril Draganiuc - Phthisiopneumology

    Chisinau, Chisinau City, Moldova · Recruiting

  • Hospital Sergio E. Bernales

    Lima, Peru · Recruiting

  • Socios en Salud Sucursal Peru

    La Molina, Lima region, Peru · Recruiting

  • Centro de Investigación del Hospital de Emergencias de Villa el Salvador

    Villa El Salvador, Lima region, Peru · Not yet recruiting

  • Silang Specialist Medical Center

    Silang, Cavite, Philippines · Recruiting

  • Tropical Disease Foundation

    Makati City, National Capital Region, Philippines · Recruiting

  • Lung Center Of The Philippines

    Quezon City, National Capital Region, Philippines · Recruiting

  • Rafael Lazatin Memorial Medical Center

    Angeles City, Pampanga, Philippines · Recruiting

  • Synergy Biomed Research Institute

    East London, Eastern Cape, South Africa · Recruiting

  • Isango Lethemba TB Res Unit (CHRU) - Jose Pearson TB Hospital

    Port Elizabeth, Eastern Cape, South Africa · Recruiting

  • The Aurum Institute - Tembisa Hospital Clinical Research Centre

    Johannesburg, Gauteng, South Africa · Recruiting

  • Clinical HIV Research Unit (CHRU) - Helen Joseph Hospital

    Johannesburg, Gauteng, South Africa · Recruiting

  • Sizwe Clinical Research Site (CHRU) - Sizwe Tropical Disease Hospital,

    Johannesburg, Gauteng, South Africa · Recruiting

  • Setshaba Research Center

    Pretoria, Gauteng, South Africa · Withdrawn

  • Perinatal HIV Research Unit (PHRU) - Chris Hani Baragwanath Academic Hospital

    Soweto, Gauteng, South Africa · Recruiting

  • Centre for the AIDS Programme of Research in South Africa (CAPRISA)

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • Klerksdorp/Tshepong Hospital Complex, Tshepong Hospital, MDR Unit

    Klerksdorp, North West, South Africa · Recruiting

  • The Aurum Institute - Rustenburg

    Rustenburg, North West, South Africa · Recruiting

  • Brooklyn Chest Hospital

    Belville, Western Cape, South Africa · Recruiting

  • UCT - Lung Infection and Immunity Unit

    Cape Town, Western Cape, South Africa · Recruiting

  • UCT Lung Institute

    Cape Town, Western Cape, South Africa · Recruiting

  • The Catholic University of Korea, Incheon St. Mary's Hospital

    Incheon, Incheon Metropolitan City, South Korea · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.